Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06319742Recruiting

Extracellular Vesicle Surface Markers In Acute Cerebrovascular Syndromes.

Role: lead

NCT03627624Completed

MCID in 30 STS Test After PR in COPD Patients

Role: collaborator

NCT01144052Phase 4Completed

Natalizumab De-escalation With Interferon Beta-1b

Role: collaborator

All 3 trials loaded